- Home
- HHS vs SCYX Comparison
HHS vs SCYX Comparison
Compare HHS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- SCYX
- Stock Information
- Founded
- HHS 1923
- SCYX 1999
- Country
- HHS United States
- SCYX United States
- Employees
- HHS N/A
- SCYX N/A
- Industry
- HHS Advertising
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- SCYX Health Care
- Exchange
- HHS Nasdaq
- SCYX Nasdaq
- Market Cap
- HHS 52.3M
- SCYX 50.3M
- IPO Year
- HHS N/A
- SCYX 2014
- Fundamental
- Price
- HHS $5.61
- SCYX $1.06
- Analyst Decision
- HHS
- SCYX Buy
- Analyst Count
- HHS 0
- SCYX 1
- Target Price
- HHS N/A
- SCYX N/A
- AVG Volume (30 Days)
- HHS 24.3K
- SCYX 174.1K
- Earning Date
- HHS 11-14-2024
- SCYX 11-06-2024
- Dividend Yield
- HHS N/A
- SCYX N/A
- EPS Growth
- HHS N/A
- SCYX N/A
- EPS
- HHS N/A
- SCYX N/A
- Revenue
- HHS $187,604,000.00
- SCYX $8,566,000.00
- Revenue This Year
- HHS N/A
- SCYX N/A
- Revenue Next Year
- HHS $4.05
- SCYX $405.82
- P/E Ratio
- HHS N/A
- SCYX N/A
- Revenue Growth
- HHS N/A
- SCYX N/A
- 52 Week Low
- HHS $5.31
- SCYX $1.06
- 52 Week High
- HHS $8.87
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- HHS 37.55
- SCYX 37.92
- Support Level
- HHS $5.52
- SCYX $1.06
- Resistance Level
- HHS $5.98
- SCYX $1.25
- Average True Range (ATR)
- HHS 0.26
- SCYX 0.07
- MACD
- HHS 0.03
- SCYX -0.01
- Stochastic Oscillator
- HHS 32.58
- SCYX 17.65
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.